The Effect of Growth Hormone Treatment on Physical Performance Indices in Children With Idiopathic Short Stature

in Pediatric Exercise Science

Click name to view affiliation

Adi WeinbergTel Aviv University

Search for other papers by Adi Weinberg in
Current site
Google Scholar
PubMed
Close
*
,
Nitzan DrorTel Aviv University

Search for other papers by Nitzan Dror in
Current site
Google Scholar
PubMed
Close
*
,
Katya MotinTel Aviv University

Search for other papers by Katya Motin in
Current site
Google Scholar
PubMed
Close
*
,
Michal PantanowitzTel Aviv University

Search for other papers by Michal Pantanowitz in
Current site
Google Scholar
PubMed
Close
*
,
Dan NemetTel Aviv University

Search for other papers by Dan Nemet in
Current site
Google Scholar
PubMed
Close
*
, and
Alon EliakimTel Aviv University

Search for other papers by Alon Eliakim in
Current site
Google Scholar
PubMed
Close
*
Restricted access

Purpose: To examine the effect of growth hormone (GH) treatment on physical performance in children with idiopathic short stature and normal GH secretion. Materials and Methods: A total of 24 children participated in the study (13 GH-treated, 11 non-treated, aged 8–13 y, 11 males and 13 females, Tanner stage 1–2). Participants performed a battery of motor skill performance tests (Eurofit), as well as the Wingate anaerobic test. Results: No statistically significant differences in any of the Eurofit physical fitness test results (eg, 20-m shuttle run 33.0 [15.1] vs 25.1 [21.0] laps in treated and nontreated participants, respectively, P = .25) or the Wingate anaerobic test were found between the groups (eg, peak power 5.0 [2.9] vs 3.9 [2.6] watts/kg in treated and nontreated participants, respectively, P = .2). Conclusions: Therapeutic usage of exogenous GH for pre and early pubertal children with idiopathic short stature and normal GH secretion was not associated with beneficial effects on physical performance indices. This suggests that the use of GH as a potential performance enhancing agent, in this age group, at least at commonly used doses, is not advantageous.

The authors are with the Child Health and Sports Center, Pediatric Endocrinology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Israel.

Nemet (dan.nemet@clalit.org.il, dnemet@gmail.com) is corresponding author.
  • Collapse
  • Expand
  • 1.

    Bar-Or O. The Wingate anaerobic test. An update on methodology, reliability and validity. Sports Med. 1987;4(6):38194. PubMed ID: 3324256 doi:10.2165/00007256-198704060-00001

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Capalbo D, Barbieri F, Improda N, et al. Growth hormone improves cardiopulmonary capacity and body composition in children with growth hormone deficiency. J Clin Endocrinol Metab. 2017;102(11):40808. PubMed ID: 28938456 doi:10.1210/jc.2017-00871

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008;93(11):42107. PubMed ID: 18782877 doi:10.1210/jc.2008-0509

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Haliloglu O, Topsakal N, Camliguney F, et al. Static and dynamic balances of patients with acromegaly and impact of exercise on balance. Pituitary. 2019;22(5):497506. PubMed ID: 31368031 doi:10.1007/s11102-019-00979-3

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hermansen K, Bengtsen M, Kjaer M, Vestergaard P, Jorgensen JOL. Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials. Growth Horm IGF Res. 2017;34:3844. PubMed ID: 28514721 doi:10.1016/j.ghir.2017.05.005

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;314:127.

  • 7.

    Leger LA, Lambert J. A maximal multistage 20-m shuttle run test to predict VO2max. Eur J Appl Physiol Occup Physiol. 1982;49(1):112. PubMed ID: 7201922

  • 8.

    Rogol AD. rhGH Abuse for Sports Performance. Pediatr Endocrinol Rev. 2018;(16 Suppl 1):1429. PubMed ID: 30378792

  • 9.

    St Clair GA, Broomhead S, Lambert MI, Hawley JA. Prediction of maximal oxygen uptake from a 20-m shuttle run as measured directly in runners and squash players. J Sports Sci. 1998;16(4):3315. doi:10.1080/02640419808559361

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Tomkinson GR, Olds TS, Borms J. Who are the Eurofittest? Med Sport Sci. 2007;50:10428. PubMed ID: 17387254

  • 11.

    World Anti-Doping Agency: List of prohibited substances and methods. 2020. https://www.wada-ama.org/en/media/news/2019-09/wada-publishes-2020-list-of-prohibited-substances-and-methods

All Time Past Year Past 30 Days
Abstract Views 1847 966 120
Full Text Views 14 3 1
PDF Downloads 15 5 2